Linvoseltamab
Linvoseltamab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Relapsed Refractory Multiple Myeloma (RRMM)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
17 项
全球在招研究
6 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Regeneron Pharmaceuticals
- Dickran Kazandjian, MD
- Multiple Myeloma Research Consortium
- Fred Hutchinson Cancer Center
- European Myeloma Network B.V.
- Dana-Farber Cancer Institute
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、Greece、日本、Poland、South Korea、英国、Brazil、Chile、中国台湾、比利时、法国
正在招募患者的 Linvoseltamab 研究
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
II 期招募中美国NCT06910124Horizon Two: HR NDMM (MMRC-100)
II 期招募中美国NCT07053436A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
I 期 / II 期招募中澳大利亚GreeceNCT07455851A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
III 期招募中美国日本PolandSouth KoreaNCT07393282A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
III 期招募中美国澳大利亚BrazilChileNCT07222761Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
I 期 / II 期招募中美国NCT07181941A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
II 期招募中美国比利时法国爱尔兰NCT06140524A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
III 期招募中美国澳大利亚比利时BrazilNCT05730036A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
I 期招募中美国法国GreeceIsraelNCT05137054Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
I 期 / II 期招募中美国比利时德国日本NCT03761108Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
IV 期招募中美国NCT07609940IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
II 期招募中美国NCT06376526A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
I 期 / II 期招募中美国法国西班牙NCT05828511A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
III 期招募中澳大利亚奥地利CroatiaCzechiaNCT06932562D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
III 期招募中美国NCT07624513A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
I 期 / II 期招募中美国GreeceSouth Korea西班牙NCT06292780A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
I 期 / II 期招募中澳大利亚英国NCT06669247
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。